In 2013 a pilot study took place on 30 participants with down syndrome between the ages 14 to 29 where the security and tolerance of the continuate EGCG administration for three months. Later, in 2015 a clinical trial was done on young adults (16 to 34 years old) with down syndrome (TESDAD study) and it was proven that the EGCG combined with a program of cognitive stimulation implied, compared to only cognitive stimulation, significant improvement on several areas of the memory, autonomy and in the daily competences of the participants.
At the moment, the clinical multicentric paediatric trial PERSEUS is finalised. This study aims to evaluate the security and efficacy of FontUp® in the improvement of the cognition and the functionality in the paediatric population with Down syndrome and X-Frail. This clinical trial will allow to corroborate the previous results in the study TESDAD, with the advantage that represents initiating the treatment at an earlier age where it is expected that the results can be more stable in time and therefore more significant. In a few months, the results will be available